Eden Research plc

Eden Research plc

EDNSF
Eden Research plcUS flagOther OTC
0.04
USD
- -
- -
18.08MMarket Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
Revenue per Share
- -
- -
- -
0.01
- -
0.01
0.01
0.01
- -
- -
- -
0.01
0.01
Basic EPS, GAAP
-0.02
-0.01
-0.02
-0.01
-0.01
- -
- -
-0.01
-0.01
-0.01
-0.01
-0.02
- -
Free Cash Flow per Basic Share
-0.02
-0.01
-0.01
- -
-0.01
- -
-0.01
-0.01
-0.01
-0.01
- -
-0.01
-0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.26
-0.23
-0.24
-0.2
-0.19
-0.17
-0.16
-0.17
-0.1
-0.1
-0.1
0.02
0.01
Tangible Book Value per Share
- -
- -
- -
- -
0.01
0.02
0.02
0.01
0.02
0.01
0.01
0.02
0.01
Basic Weighted Avg Shares
107
122
126
156
179
196
207
209
345
380
381
421
533
Sales/Revenue/Turnover
- -
- -
- -
1
- -
2
3
2
1
1
2
3
4
Operating Margin (%)
-3,674.94
-1,975.65
-1,748.17
-128.9
-481.27
-71.99
-17.92
-74.37
-163.86
-261.14
-140.49
-58.48
-50.81
Depreciation Expense
1
1
1
1
1
1
- -
1
1
1
1
6
1
Net Income, GAAP
-2
-2
-3
-1
-2
-1
- -
-1
-2
-3
-2
-6
-2
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-5,186.32
-1,979.37
-2,973.78
-131
-467.17
-34.05
-12.07
-62.71
-165.84
-227.01
-122.44
-203.45
-44.31
Working Capital
- -
- -
- -
- -
1
3
3
1
8
4
2
8
4
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
6
6
6
6
7
9
8
7
15
13
11
14
12
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-34.79

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.21%
17.27%
-12.61%
Free Cash Flow
80.62%
24.04%
4.32%
Net Income, GAAP
34.73%
44.21%
-70.64%
Sales/Revenue/Turnover
124.44%
24.59%
34.79%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
3
2024
- -
- -
- -
- -
4
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.02
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Sean Michael Smith
Full Time Employees
23
Sector
Basic Materials
Industry
Agricultural Inputs
Address
67C Innovation Drive Abingdon United Kingdom OX14 4RQ
IPO Date
Aug 12, 2021
Business
Eden Research plc develops and supplies biopesticide products and natural microencapsulation technologies using its proprietary plastic-free Sustaine platform to the global crop protection, animal health, and consumer products industries. The company offers crop protection solutions including Mevalone, a biofungicide for foliar diseases such as Botrytis, powdery mildew, and downy mildew in open-field, greenhouse, and high-value fruit and vegetable crops; Cedroz, a terpene-based nematicide targeting soil pests like root-knot nematodes in collaboration with Eastman Chemical; and Ecovelex, a seed treatment product; as well as animal health products encompassing shampoos, conditioners, skin disease controls, odour controls, flea and tick treatments, parasite treatments, and insect sprays; and consumer products such as head-lice treatments, deodorants, odour neutralisers, fragrances, wound-care solutions, and food flavourings. Eden Research plc operates primarily in Europe, the United Kingdom, Kenya, Australia, the United States, and Italy, targeting growers, farmers, horticulturists, and agricultural input distributors with low-residue, sustainable alternatives to conventional pesticides. Founded in 1995 and headquartered at 67C Innovation Drive, Milton Park, Abingdon, Oxfordshire, England, the AIM-quoted company (ticker: EDEN.L; OTC: EDNSF) focuses on the agrochemical segment alongside biocides, human health, and animal health. Recent developments include regulatory approval for Mevalone against powdery mildew on grapes in California in May 2025; a Knowledge Transfer Partnership grant from Innovate UK and strategic collaboration with Royal Holloway, University of London, announced in June 2025 to accelerate Ecovelex seed treatment expansion; temporary authorisation for Ecovelex-treated maize seeds in Italy in November 2025 for the 2026 growing season; ongoing partnerships with SCP Cam, Moxen, Eastman Chemical for Cedroz commercialisation and expansion, Corta for animal health products like Eelic in Europe, and others for market development in nematodes, metritis treatments, and new territories.

Company News

APIChatGPT